Haleon Regulatory News (HLN)

Haleon plc: Board Change

30 April 2025: Haleon plc (the "Company" or "Haleon") today announces the appointment of Matt Shattock as independent Non-Executive Director with effect from 1 June 2025.

Matt brings significant innovation, operational and executive leadership experience in consumer goods and retail to Haleon. Matt is currently the Lead Independent Director of The Clorox Company and a non-executive director of VF Corporation. Matt was previously the Chairman of Domino's Pizza Group plc from 2020 to 2025. He was also President and CEO of Beam Suntory Inc., from 2009 to 2020, where he led the successful integration of the Beam and Suntory spirits businesses and delivered brand portfolio transformation and accelerated global growth.

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to welcome Matt to Haleon. Matt's track record in building innovative brands, driving operational excellence and sustained value creation across multiple global consumer businesses as well as his substantial knowledge of the North American market will add significant strengths to our Board."

The Company confirms that there is no further information to be disclosed under the requirements of UKLR 6.4.6R and 6.4.8R.

Amanda Mellor 

Company Secretary 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.